ARDT vs INBX: Which Stock Is the Better Buy?
Ardent Health, Inc. and Inhibrx Biosciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ARDT vs INBX, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Ardent Health, Inc. (ARDT) | Inhibrx Biosciences, Inc. (INBX) | |
|---|---|---|
| Market cap | $1.4B | $1.3B |
| Revenue (latest FY) | $6.32B | $1.30M |
| Net income (latest FY) | $135.81M | $-140.06M |
| Revenue growth (5y CAGR) | 7.2% | -0.0% |
| Net margin | 2.1% | -10773.5% |
| Return on equity | 8.1% | -1752.2% |
| P/E ratio | 9.9 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 4 | 1 |
| Positive free cash flow | Yes | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full ARDT vs INBX breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ARDT's full financials → Open INBX's full financials →More comparisons
Frequently asked questions
Which is bigger, ARDT or INBX?
Ardent Health, Inc. is larger by market capitalization — $1.4B versus $1.3B.
Which grows faster, ARDT or INBX?
Over the last five fiscal years, Ardent Health, Inc. grew revenue faster — 7.2%/yr versus -0.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
ARDT fundamentals → · INBX fundamentals → · All 1,500+ companies → · Free screener →